Patterns of care and outcomes of adjuvant therapy for high-risk head and neck cancer after surgery

被引:10
|
作者
Osborn, Virginia Wedell [1 ,2 ]
Givi, Babak [1 ,3 ]
Rineer, Justin [4 ]
Roden, Dylan [1 ,3 ]
Sheth, Niki [1 ,2 ]
Lederman, Ariel [1 ,2 ]
Katsoulakis, Evangelia [5 ]
Hu, Kenneth [3 ]
Schreiber, David [1 ,2 ]
机构
[1] New York Harbor Healthcare Syst, Dept Vet Affairs, New York, NY USA
[2] Suny Downstate Med Ctr, Brooklyn, NY 11203 USA
[3] NYU, Langone Med Ctr, New York, NY USA
[4] UF Hlth Canc Ctr, Orlando Hlth, Orlando, FL USA
[5] James A Haley Vet Hosp, Dept Vet Affairs, Tampa, FL 33612 USA
关键词
antineoplastic agents; head and neck neoplasms; operative procedures; radiation; surgical procedures; SQUAMOUS-CELL CARCINOMA; LOCALLY ADVANCED HEAD; POSITIVE MARGINS; CHEMOTHERAPY; RADIOTHERAPY; DISPARITIES; SURVIVAL; IMPACT;
D O I
10.1002/hed.25103
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
BackgroundPostoperative chemoradiotherapy (CRT) is considered standard of care in patients with locally advanced head and neck cancer with positive margins and/or extracapsular extension (ECE). MethodsThe National Cancer Data Base (NCDB) was queried to identify patients with squamous cell carcinoma of the head and neck with stages III to IVB disease or with positive margins and/or ECE diagnosed between 2004 and 2012 receiving postoperative radiotherapy (RT). Using univariable and multivariable logistic and Cox regression, we assessed for predictors of CRT use and covariables impacting overall survival (OS), including in a propensity-matched subset. ResultsOf 12224 patients, 67.1% with positive margins and/or ECE received CRT as well as 54.0% without positive margins and/or ECE. The 5-year OS was 61.6% for RT alone versus 67.4% for CRT. In the propensity-matched cohort, OS benefit persisted with CRT, including in a subset with positive margins and/or ECE but not without. ConclusionPostoperative CRT seems underutilized with positive margins and/or ECE and overutilized without positive margins and/or ECE. The CRT was associated with improved OS but the benefit persisted only in the subset with positive margins and/or ECE.
引用
收藏
页码:1254 / 1262
页数:9
相关论文
共 50 条
  • [1] Patterns of Care and Outcomes of Adjuvant Therapy for High Risk Head and Neck Cancer After Surgery
    Osborn, V. W.
    Givi, B.
    Roden, D. F.
    Katsoulakis, E.
    Sheth, N.
    Lederman, A. J.
    Schwartz, D.
    Schreiber, D.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (02): : E363 - E364
  • [2] Adjuvant Chemoradiation in High-Risk Head and Neck Cancer
    Torres, S.
    Ferreira, M.
    Sargento, I.
    Oliveira, J. O. A. O.
    [J]. EUROPEAN JOURNAL OF CANCER, 2011, 47 : S553 - S553
  • [3] Assessment of adjuvant therapy in resected head and neck cancer with high-risk features
    Ajmani, Gaurav S.
    Nocon, Cheryl C.
    Wang, Chi-Hsiung
    Bhayani, Mihir K.
    [J]. ORAL ONCOLOGY, 2017, 74 : 15 - 20
  • [4] Trends and Implications of Adjuvant Systemic Therapy for Head and Neck Cancer Without High-Risk Features
    Armstrong, Austin T.
    Velez-Velez, Lisa M.
    Simpson, Matt C.
    Massa, Sean T.
    [J]. OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 2023, : 556 - 569
  • [5] Surgery and Adjuvant Radiation for High-risk Skin Adnexal Carcinoma of the Head and Neck
    Wang, Lora S.
    Handorf, Elizabeth A.
    Wu, Hong
    Liu, Jeffrey C.
    Perlis, Clifford S.
    Galloway, Thomas J.
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2017, 40 (04): : 429 - 432
  • [6] Assessment of Erlotinib as Adjuvant Chemoprevention in High-Risk Head and Neck Cancer Patients
    Rosenthal, Eben L.
    Chung, Thomas K.
    Carroll, William R.
    Clemons, Lisa
    Desmond, Renee
    Nabell, Lisle
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2014, 21 (13) : 4263 - 4269
  • [7] Assessment of Erlotinib as Adjuvant Chemoprevention in High-Risk Head and Neck Cancer Patients
    Eben L. Rosenthal
    Thomas K. Chung
    William R. Carroll
    Lisa Clemons
    Renee Desmond
    Lisle Nabell
    [J]. Annals of Surgical Oncology, 2014, 21 : 4263 - 4269
  • [8] TREATMENT FAILURE IN HIGH-RISK HEAD AND NECK CANCER TREATED WITH ADJUVANT CHEMORADIATION
    Torres, S.
    Marques, M. T.
    Ferreira, M.
    Sargento, I.
    Netto, E.
    Oliveira, J.
    Roldao, M.
    Moreira, A.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 345 - 346
  • [9] Phase I Adjuvant Radiation With Docetaxel in High-Risk Head and Neck Cancer
    Clark, Joseph I.
    Eisner, Robert M.
    Hofmeister, Craig
    Norton, John
    Thomas, Sachdev
    Choudhury, Abdul
    Petruzzelli, Guy
    Lathers, Deanne
    Young, M. Rita I.
    Lau, Ann
    Emami, Bahman
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2009, 32 (04): : 396 - 400
  • [10] Chemoradiation after surgery for high-risk head and neck cancer patients: How strong is the evidence?
    Bernier, J
    Cooper, JS
    [J]. ONCOLOGIST, 2005, 10 (03): : 215 - 224